Hu Yuan, Zhou Xiao-Jiang, Liu Ping, Dong Xian-Zhe, Mu Li-Hua, Chen Yi-Bang, Liu Ming-Yue, Yu Bing-Ying
Department of Clinical Pharmacology, Chinese PLA General Hospital, Beijing, China.
Neuropsychobiology. 2014;69(3):129-39. doi: 10.1159/000358089. Epub 2014 Apr 26.
Depression has been associated with reduced expression of brain-derived neurotrophic factor (BDNF) in the hippocampus. Previous studies have demonstrated that the herbal medicine formula, 'kaixinsan' (KXS), could ameliorate the severity of depression and increase cAMP response element-binding protein expression. There is direct evidence suggesting that the reduction of the BDNF protein in specific brain sites can provoke depressive-like behaviour or affect neurogenesis in vivo. However, the biological mechanisms between the antidepressant and neuroprotective effect of KXS and the alterations in BDNF levels in in vivo and in vitro models remain unclear. Using BDNF knockdown mediated by lentiviral vectors (LV-shBDNF-3) transfected with primary hippocampal neurons and following injection into the dentate gyrus of the hippocampus, it was demonstrated that a reduction in BDNF expression affects cell viability and animal behaviours associated with depression. During treatment with KXS after the lentiviral shRNA silencing of BDNF in cell and animal, cell viability, body weight, the sucrose preference test (SPT), the open field test (OFT) the Morris Water Maze (MWM) task and BDNF expression were measured. KXS attenuated LV-shBDNF-3-induced cell death in primary hippocampal neurons and also improved the sucrose intake in SPT, ambulatory response in OFT and learning ability in MWM against LV-shBDNF-3-induced depressive-like syndromes. Moreover, immunoblot analysis confirmed that KXS could reverse LV-shBDNF-induced BDNF reduction either in vitro or in vivo. These findings provide substantial evidence for supporting a neurotrophic hypothesis of depression and specify BDNF targets for potential antidepressant interventions. Moreover, the antagonism between LV-shRNA BDNF knockdown and KXS may depend on multiple compounds with synergistic mechanisms that modulate the different signal transduction networks directly or indirectly, increasing BDNF expression and exerting its neuroprotective and antidepressant-like effects.
抑郁症与海马体中脑源性神经营养因子(BDNF)表达降低有关。先前的研究表明,中药方剂“开心散”(KXS)可改善抑郁症的严重程度并增加环磷腺苷效应元件结合蛋白的表达。有直接证据表明,特定脑区BDNF蛋白的减少可引发抑郁样行为或影响体内神经发生。然而,KXS的抗抑郁和神经保护作用与体内外模型中BDNF水平变化之间的生物学机制仍不清楚。通过用慢病毒载体(LV-shBDNF-3)介导的BDNF敲低转染原代海马神经元,并将其注射到海马齿状回后,证明BDNF表达降低会影响细胞活力以及与抑郁相关的动物行为。在细胞和动物中用慢病毒shRNA沉默BDNF后进行KXS治疗期间,测量细胞活力、体重、蔗糖偏好试验(SPT)、旷场试验(OFT)、莫里斯水迷宫(MWM)任务和BDNF表达。KXS减轻了LV-shBDNF-3诱导的原代海马神经元细胞死亡,还改善了SPT中的蔗糖摄入量、OFT中的自主活动反应以及MWM中针对LV-shBDNF-3诱导的抑郁样综合征的学习能力。此外,免疫印迹分析证实,KXS在体外或体内均可逆转LV-shBDNF诱导的BDNF减少。这些发现为支持抑郁症的神经营养假说提供了大量证据,并明确了潜在抗抑郁干预的BDNF靶点。此外,LV-shRNA BDNF敲低与KXS之间的拮抗作用可能取决于多种具有协同机制的化合物,这些化合物直接或间接调节不同的信号转导网络,增加BDNF表达并发挥其神经保护和抗抑郁样作用。